{"disease":{"id":"pseudomembranous-colitis","name":"pseudomembranous colitis"},"drugs":{"marketed":[{"drug_id":"fidaxomicin","indication_name":"Pseudomembranous enterocolitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dificid","generic_name":"FIDAXOMICIN","company_name":"Cubist Pharms Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Macrolide Antibacterial [EPC]","quality_score":65,"revenue":"410.0","mechanism":"Dificid works by inhibiting protein synthesis in bacteria, preventing them from reproducing and causing infection."},{"drug_id":"vancomycin","indication_name":"Pseudomembranous enterocolitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vancocin","generic_name":"vancomycin","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase","drug_class":"","quality_score":40,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04014413","title":"Safety and Efficacy of Fecal Microbiota Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT00304863","title":"Addition of Lactobacillus to Metronidazole in Treatment of CDAD","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Michael E. DeBakey VA Medical Center","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}